A citation-based method for searching scientific literature

Kerstin Rhiem, Hans-Joachim Bücker-Nott, Martin Hellmich, Holger Fischer, Beyhan Ataseven, Christine Dittmer-Grabowski, Kunibert Latos, Volker Pelzer, Manuela Seifert, Andrea Schmidt, Daniela Rezek, Ulrich Groh, Wolfgang Meinerz, Dirk Crommelinck, Eric Hahnen, Simone Wesselmann, Rita Katharina Schmutzler. Breast J 2019
Times Cited: 15







List of co-cited articles
78 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
80

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle,[...]. J Med Genet 2016
95
60

High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Ulrich Bick, Christoph Engel, Barbara Krug, Walter Heindel, Eva M Fallenberg, Kerstin Rhiem, David Maintz, Michael Golatta, Dorothee Speiser, Dorothea Rjosk-Dendorfer,[...]. Breast Cancer Res Treat 2019
44
40

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
894
33

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Philipp Harter, Jan Hauke, Florian Heitz, Alexander Reuss, Stefan Kommoss, Frederik Marmé, André Heimbach, Katharina Prieske, Lisa Richters, Alexander Burges,[...]. PLoS One 2017
63
33

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Christoph Engel, Kerstin Rhiem, Eric Hahnen, Sibylle Loibl, Karsten E Weber, Sabine Seiler, Silke Zachariae, Jan Hauke, Barbara Wappenschmidt, Anke Waha,[...]. BMC Cancer 2018
36
26

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Alfons Meindl, Heide Hellebrand, Constanze Wiek, Verena Erven, Barbara Wappenschmidt, Dieter Niederacher, Marcel Freund, Peter Lichtner, Linda Hartmann, Heiner Schaal,[...]. Nat Genet 2010
481
26

Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Xiao Li, Ran You, Xinwei Wang, Congxin Liu, Zicheng Xu, Jin Zhou, Bin Yu, Ting Xu, Hongzhou Cai, Qing Zou. Clin Cancer Res 2016
91
26

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
20

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
171
20

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.
Barbara Wappenschmidt, Jan Hauke, Ulrike Faust, Dieter Niederacher, Lisa Wiesmüller, Gunnar Schmidt, Evi Groß, Andrea Gehrig, Christian Sutter, Juliane Ramser,[...]. Geburtshilfe Frauenheilkd 2020
8
37

Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.
Alfons Meindl, Nina Ditsch, Karin Kast, Kerstin Rhiem, Rita K Schmutzler. Dtsch Arztebl Int 2011
79
20

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Bernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, A Inge-Marie Obdeijn, Margriet Collée, Hanne E J Meijers-Heijboer, Denise J Jenner, Hester S A Oldenburg, Klaartje van Engelen, Jakob de Vries,[...]. Breast Cancer Res Treat 2019
53
20

Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Lisa Krassuski, Vera Vennedey, Stephanie Stock, Sibylle Kautz-Freimuth. BMC Med Inform Decis Mak 2019
13
23

Decision aids for people facing health treatment or screening decisions.
Dawn Stacey, France Légaré, Krystina Lewis, Michael J Barry, Carol L Bennett, Karen B Eden, Margaret Holmes-Rovner, Hilary Llewellyn-Thomas, Anne Lyddiatt, Richard Thomson,[...]. Cochrane Database Syst Rev 2017
20

"When information is not enough": A model for understanding BRCA-positive previvors' information needs regarding hereditary breast and ovarian cancer risk.
Marleah Dean, Courtney L Scherr, Meredith Clements, Rachel Koruo, Jennifer Martinez, Amy Ross. Patient Educ Couns 2017
27
20


Development and evaluation of a decision aid for BRCA carriers with breast cancer.
Julie O Culver, Deborah J MacDonald, Andrea A Thornton, Sharon R Sand, Marcia Grant, Deborah J Bowen, Harry Burke, Nellie Garcia, Kelly A Metcalfe, Jeffrey N Weitzel. J Genet Couns 2011
22
20

Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
Bernadette A M Heemskerk-Gerritsen, Matti A Rookus, Cora M Aalfs, Margreet G E M Ausems, Johanna M Collée, Liesbeth Jansen, C Marleen Kets, Kristien B M I Keymeulen, Linetta B Koppert, Hanne E J Meijers-Heijboer,[...]. Int J Cancer 2015
95
20

Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.
Christine Rini, Suzanne C O'Neill, Heiddis Valdimarsdottir, Rachel E Goldsmith, Lina Jandorf, Karen Brown, Tiffani A DeMarco, Beth N Peshkin, Marc D Schwartz. Health Psychol 2009
32
20

Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
Francesca De Felice, Claudia Marchetti, Angela Musella, Innocenza Palaia, Giorgia Perniola, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici. Ann Surg Oncol 2015
41
20

Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
K A Metcalfe, A Poll, A O'Connor, S Gershman, S Armel, A Finch, R Demsky, B Rosen, S A Narod. Clin Genet 2007
53
20

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion Kiechle, Nina Ditsch, Wolfgang Janni, Christoph Mundhenke, Michael Golatta,[...]. Breast Cancer Res 2012
61
20

Toward Minimum Standards for Certifying Patient Decision Aids: A Modified Delphi Consensus Process.
Natalie Joseph-Williams, Robert Newcombe, Mary Politi, Marie-Anne Durand, Stephanie Sivell, Dawn Stacey, Annette O'Connor, Robert J Volk, Adrian Edwards, Carol Bennett,[...]. Med Decis Making 2014
256
20

A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
Marline G Harmsen, Miranda P Steenbeek, Nicoline Hoogerbrugge, Helena C van Doorn, Katja N Gaarenstroom, M Caroline Vos, Leon F A G Massuger, Joanne A de Hullu, Rosella P M G Hermens. Health Expect 2018
12
25

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M Dunning, James Redman, James Scarth, Inga Plaskocinska,[...]. J Clin Oncol 2020
146
20

Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.
Patricia Ashton-Prolla, Juliana Giacomazzi, Aishameriane V Schmidt, Fernanda L Roth, Edenir I Palmero, Luciane Kalakun, Ernestina S Aguiar, Susana M Moreira, Erica Batassini, Vanessa Belo-Reyes,[...]. BMC Cancer 2009
44
13

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
A C Antoniou, P D P Pharoah, G McMullan, N E Day, M R Stratton, J Peto, B J Ponder, D F Easton. Br J Cancer 2002
317
13

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Christine Fischer, Karoline Kuchenbäcker, Christoph Engel, Silke Zachariae, Kerstin Rhiem, Alfons Meindl, Nils Rahner, Nicola Dikow, Hansjörg Plendl, Irmgard Debatin,[...]. J Med Genet 2013
50
13

Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
J Peto, N Collins, R Barfoot, S Seal, W Warren, N Rahman, D F Easton, C Evans, J Deacon, M R Stratton. J Natl Cancer Inst 1999
646
13

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
185
13


Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
376
13

Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
282
13

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Andrew Lee, Nasim Mavaddat, Amber N Wilcox, Alex P Cunningham, Tim Carver, Simon Hartley, Chantal Babb de Villiers, Angel Izquierdo, Jacques Simard, Marjanka K Schmidt,[...]. Genet Med 2019
192
13

10-year performance of four models of breast cancer risk: a validation study.
Mary Beth Terry, Yuyan Liao, Alice S Whittemore, Nicole Leoce, Richard Buchsbaum, Nur Zeinomar, Gillian S Dite, Wendy K Chung, Julia A Knight, Melissa C Southey,[...]. Lancet Oncol 2019
76
13

Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
Sarah Reid, Detlev Schindler, Helmut Hanenberg, Karen Barker, Sandra Hanks, Reinhard Kalb, Kornelia Neveling, Patrick Kelly, Sheila Seal, Marcel Freund,[...]. Nat Genet 2007
445
13

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Hermela Shimelis, Holly LaDuca, Chunling Hu, Steven N Hart, Jie Na, Abigail Thomas, Margaret Akinhanmi, Raymond M Moore, Hiltrud Brauch, Angela Cox,[...]. J Natl Cancer Inst 2018
151
13

Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.
Bronson D Riley, Julie O Culver, Cécile Skrzynia, Leigha A Senter, June A Peters, Josephine W Costalas, Faith Callif-Daley, Sherry C Grumet, Katherine S Hunt, Rebecca S Nagy,[...]. J Genet Couns 2012
205
13


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
13

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
851
13

Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.
Marije F Bakker, Stéphanie V de Lange, Ruud M Pijnappel, Ritse M Mann, Petra H M Peeters, Evelyn M Monninkhof, Marleen J Emaus, Claudette E Loo, Robertus H C Bisschops, Marc B I Lobbes,[...]. N Engl J Med 2019
195
13

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Sepideh Saadatmand, Inge-Marie Obdeijn, Emiel J Rutgers, Jan C Oosterwijk, Rob A Tollenaar, Gwendolyn H Woldringh, Elisabeth Bergers, Cornelis Verhoef, Eveline A Heijnsdijk, Maartje J Hooning,[...]. Int J Cancer 2015
54
13


A systematic development process for patient decision aids.
Angela Coulter, Diana Stilwell, Jennifer Kryworuchko, Patricia Dolan Mullen, Chirk Jenn Ng, Trudy van der Weijden. BMC Med Inform Decis Mak 2013
268
13

Geography and the debate over Medicare reform.
John E Wennberg, Elliott S Fisher, Jonathan S Skinner. Health Aff (Millwood) 2002
269
13

Shared decision making: a model for clinical practice.
Glyn Elwyn, Dominick Frosch, Richard Thomson, Natalie Joseph-Williams, Amy Lloyd, Paul Kinnersley, Emma Cording, Dave Tomson, Carole Dodd, Stephen Rollnick,[...]. J Gen Intern Med 2012
13

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics.
Claire Julian-Reynier, Anne-Déborah Bouhnik, Emanuelle Mouret-Fourme, Marion Gauthier-Villars, Pascaline Berthet, Christine Lasset, Jean-Pierre Fricker, Olivier Caron, Paul Gesta, Elisabeth Luporsi,[...]. Genet Med 2010
29
13

Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
R Manchanda, M Burnell, A Abdelraheim, M Johnson, A Sharma, E Benjamin, C Brunell, E Saridogan, S Gessler, D Oram,[...]. BJOG 2012
43
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.